Single versus sequential high-dose chemotherapy (HOCT) in patients with relapsed or refractory germ-cell tumors (GCT).

被引：0
|
作者：
Lorch, A.
Rick, O.
Hartmann, J. T.
Kollmannsberger, C.
Metzner, B.
Schmidt-Wolf, I.
Berdel, W. E.
Schirren, R.
Beyer, J.
Bokemeyer, C.
机构：
[1] Univ Hosp, Marburg, Germany
[2] Klin Reinhardshoehe, Bad Wildungen, Germany
[3] Univ Hosp, Tubingen, Germany
[4] BC Canc Agcy, Vancouver, BC, Canada
[5] Staedt Kliniken, Oldenburg, Germany
[6] Univ Hosp Bonn, Bonn, Germany
[7] Univ Hosp, Munster, Germany
[8] Oberschwabenklin, Ravensburg, Germany
[9] Univ Hosp, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：219S / 219S
页数：1
相关论文
共 50 条
  • [1] Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?
    Feldman, Darren R.
    Motzer, Robert J.
    Bajorin, Dean F.
    NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (02): : 78 - 79
  • [2] Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?
    Darren R Feldman
    Robert J Motzer
    Dean F Bajorin
    Nature Clinical Practice Urology, 2008, 5 : 78 - 79
  • [3] High-dose chemotherapy in refractory or relapsed germ cell tumors - Results from sequential trials
    Beyer, J
    Bokemeyer, C
    Rick, O
    Metzner, B
    Casper, J
    Wandt, H
    Hartmann, F
    Schmoll, HJ
    Derigs, G
    Kanz, L
    Huhn, D
    Siegert, W
    BONE MARROW TRANSPLANTATION, 1998, 22 : S43 - S44
  • [4] Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
    Nieto, Yago
    Tannir, Nizar M.
    Tu, Shi-Ming
    Jones, Roy B.
    Zurita, Amado J.
    Aparicio, Ana
    Bassett, Roland
    Margolin, Kim Allyson
    Holmberg, Leona
    Champlin, Richard E.
    Pagliaro, Lance C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] High-dose chemotherapy in germ-cell tumors
    Droz, JP
    Culine, S
    Biron, P
    Kramar, A
    ANNALS OF ONCOLOGY, 1996, 7 (10) : 997 - 1003
  • [6] Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial
    Lorch, Anja
    Kleinhans, Antje
    Kramar, Andrew
    Kollmannsberger, Christian K.
    Hartmann, Joerg T.
    Bokemeyer, Carsten
    Rick, Oliver
    Beyer, Joerg
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 800 - 805
  • [7] High-dose chemotherapy in patients with germ-cell tumors 2010
    Bokemeyer, C.
    Honecker, F.
    Oechsle, K.
    Lorch, A.
    Beyer, J.
    ONKOLOGIE, 2010, 33 : 91 - 91
  • [8] High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors
    Lorch, A.
    Neubauer, A.
    Hackenthal, M.
    Dieing, A.
    Hartmann, J. T.
    Rick, O.
    Bokemeyer, C.
    Beyer, J.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 820 - 825
  • [9] Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients
    Lorch, A.
    Mollevi, C.
    Kramar, A.
    Einhorn, L. H.
    Necchi, A.
    Massard, C.
    DeGiorgi, U.
    Flechon, A.
    Margolin, K. A.
    Beyer, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] High-Dose Chemotherapy in Relapsed or Refractory Metastatic Germ-Cell Cancer: The Scotland Experience
    Tan, Yun Yi
    Al-Bubseeree, Bahaa
    Irvine, David
    MacDonald, Graham
    McQuaker, Grant
    Parker, Anne
    Waterston, Ashita
    White, Jeff
    CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : 125 - 131
12345